Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients.
Athanasios ChalkiasAngeliki MouzarouEvangelia SamaraTheodoros XanthosEleni IschakiIoannis PantazopoulosPublished in: Molecular diagnosis & therapy (2020)
The novel coronavirus infection has spread worldwide, causing a wide spectrum of clinical manifestations. Most patients develop moderate clinical illness, but a substantial number will experience severe pneumonia, which may rapidly progress to acute respiratory distress syndrome and multiple organ failure. In this population, soluble urokinase plasminogen activator receptor (suPAR) could serve as a quick triage test and independent marker of clinical severity, hospital and intensive care unit admission, complications, and mortality.
Keyphrases
- acute respiratory distress syndrome
- emergency department
- intensive care unit
- mechanical ventilation
- extracorporeal membrane oxygenation
- end stage renal disease
- risk factors
- ejection fraction
- sars cov
- chronic kidney disease
- healthcare
- prognostic factors
- early onset
- patient reported outcomes
- coronary artery disease
- binding protein
- patient reported